Skip to content

Beam Therapeutics

US · BEAM #2614 by market cap Listed 2020
20.90 -0.04 -0.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
    Market Newswire · 2026/11/11
  • Rating change
    BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $41
    Market Newswire · 2026/11/4
  • Citi Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $68
    Market Newswire · 2026/11/11
  • Rating change
    Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
    Dow Jones · 2026/10/16
  • These Analysts Think Beam Therapeutics Inc.'s (NASDAQ:BEAM) Sales Are Under Threat
    Simply Wall St · 2026/11/5
  • Rating change
    BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $43
    Market Newswire · 2026/10/28
  • Rating change
    Maxim Group Maintains Beam Global(BEEM.US) With Buy Rating, Maintains Target Price $3
    Market Newswire · 2026/10/21
  • Rating change
    Evercore Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/10/29
  • Company notice
    Beam Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Evans John M.
    SEC · 2026/10/17
  • Rating change
    Jefferies Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $49
    Market Newswire · 2026/11/4
  • CCORF Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $78
    Market Newswire · 2026/11/11
  • Company notice
    Beam Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Evans John M.
    SEC · 2026/4/7
  • Rating change
    CCORF Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $79
    Market Newswire · 2026/10/29
  • Rating change
    Guggenheim Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $51
    Market Newswire · 2026/11/5
  • Company notice
    Beam Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Evans John M.
    SEC · 2026/4/2
  • Company notice
    4: Beam Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Evans John M.
    SEC · 2026/7/2
  • CCORF Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $78
    Market Newswire · 2026/11/4
  • Rating change
    RBC Capital Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Raises Target Price to $26
    Market Newswire · 2026/11/4
  • Company notice
    Okabe: Regarding the release of the "Slab Dandol" side‑hanging hardware for main joists and the "Sokoukeitai" bottom support for beam formwork.
    JPX · 2026/10/5
  • Rating change
    Wedbush Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $33
    Market Newswire · 2026/11/11
  • Rating change
    Freedom Capital Markets Downgrades Beam Global(BEEM.US) to Hold Rating, Maintains Target Price $1.5
    Market Newswire · 2026/8/26
  • Rating change
    Maxim Group Maintains Beam Global(BEEM.US) With Buy Rating, Cuts Target Price to $3
    Market Newswire · 2026/8/22
  • Rating change
    JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/9/9
  • Rating change
    J.P. Morgan Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $44
    Market Newswire · 2026/8/7
  • Rating change
    HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
    Benzinga · 2026/10/15

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:41 · For reference only, not investment advice and not tailored to your situation.

Beam Therapeutics discussion 0 comments

Add a comment